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Dengue virus is the most common mosquito-borne viral infection in the world, with more than 
500,000 cases of symptomatic dengue infection reported annually. Children are more susceptible to 
severe forms of the disease, including dengue hemorrhagic fever/dengue shock syndrome, and 
therefore they are more likely to require hospitalization. For these reasons, considerable effort has 
been directed towards the development of a vaccine, and several candidates have entered clinical 
trials. However, with nearly 3 billion people at risk of infection, even if a vaccine were approved 
today, we would not be able to adequately vaccinate everyone at risk. Therefore, Drs. Dennis Chao 
and M. Elizabeth Halloran (Vaccine and Infectious Disease Division), in collaboration with 
investigators from the Dengue Vaccine Initiative and the University of Florida, developed a 
computational model of infection and vaccination to determine how to most effectively deliver a 
limited supply of Dengue virus vaccine. 
The team developed a model designed to simulate seasonal dengue virus transmission in a semi-
rural region of Thailand with exposure to all four dengue virus serotypes. The model simulates a 
population of 207,591 individuals that spend time at home and at work or school. Each of these 
individuals is classified as susceptible, exposed, infectious, or recovered. Symptomatic individuals 
may remain home until they recover, while recovered individuals are immune to infection with all 
Dengue virus serotypes for the first 120 days after infection, and then only to the specific serotype 
they had been infected with. Similarly, the model simulates two populations of mosquitos. Uninfected 
mosquitos remain in a given building until they bite an infected human. After an incubation period, 
these infected mosquitos can transmit dengue virus to susceptible humans, and will occasionally 
migrate to nearby buildings. 
During the simulation, the authors seeded the epidemic by randomly exposing two people to each 
serotype daily to simulate the influx of dengue virus infected mosquitos from neighboring regions. 
The simulated season peaked in the July-August period, and resulted in a 5% infection attack rate, 
which measures the number of infected people relative to the number of exposed people. These 
infected people went on to infect an additional 1.9 to 2.3 people, a value known as the reproductive 
number, R. These values correspond closely with the observed values for dengue virus infection in  
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Thailand. Using these data, the authors determined that approximately 80% of the total population 
would need to be vaccinated to control dengue infection, a number unlikely to be met during the first 
years of vaccine availability. 
The authors simulated several 10 year vaccine roll-out strategies. In one simulation, only children 2-
14 years old were vaccinated, reaching 70% vaccination of this population after three years, and 
then continuing to vaccinate only 2-year-olds. Under these conditions, dengue virus incidence 
dropped by approximately 60% over the first three years. After the first three years, however, when 
only 2-year-olds are being vaccinated, the incidence declined much more slowly. Therefore, the 
team asked what would happen if a “catch up” vaccination program was initiated for adults after the 
initial three year vaccination program for children. Including adults in the later vaccine program 
resulted in a faster decrease in incidence after the first three years, relative to vaccinating only 
children. 
This simulation suggests that targeted vaccination of children would be the most efficient use of 
limited dengue virus vaccine stocks, particularly in reducing hospital visits and the most severe 
disease. Unfortunately, vaccination of children alone, according to this model, will be insufficient to 
stop dengue transmission. Therefore, once children are protected, a catch-up vaccination strategy to 
inoculate adults would continue the rapid decline in dengue virus infection. It is important to note that 
these results apply to a hyperendemic area and a vaccine effective against all four serotypes of the 
virus. Some vaccines currently in clinical trials do not protect against all four serotypes, and may 
require different vaccination strategies to most efficiently protect the population. 
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Image modified from Chao, et al., PLOS NTDS, 2012. 
Schematic diagram of the dengue transmission model, diagramming how human 
movement (top left), or mosquito movement (top right) is simulated. Bottom 
images display the incidence of newly infected (black) and symptomatic (red) 
patients in the case of no vaccine (bottom left), or after vaccinating 70% of 
children (bottom right). 
 
